SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE is trending as community members express bullish sentiment and highlight its strong community-driven nature, referencing the revival of OG meme culture through rage comics. The community emphasizes building, conviction, and collaboration with other meme projects, while encouraging others to 'RAGE on' despite market conditions. Discussions also mention its branching out to other social platforms.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community discusses its potential integration with major payment systems and upcoming news. The ISO 20022 compliance and possible partnerships are key talking points, with some comparing it to early-stage XRP. Community members are actively strategizing on staking and accumulating more ZBCN.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet ($STRK) is trending as discussions revolve around its potential as a scaling solution for both Ethereum and Bitcoin, particularly with the recent advancements in BTCFi. Community members highlight its quantum-resistant technology and growing ecosystem, emphasizing its role in enabling privacy and scalability in decentralized finance. The focus is on staking and the potential for substantial returns.

AlienBase

AlienBase ($ALB) is trending as community members discuss its potential, comparing it to Aerodrome ($AERO) while highlighting its smaller market cap and unique features like limit orders. Some users point to a potential Coinbase listing for Base network tokens, while others note its recent price movements and discuss optimal buying strategies. The conversation also includes discussions about staking rewards and the overall bullish sentiment surrounding the Base ecosystem.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is trending as community members discuss its potential for significant gains, drawing comparisons to Bitcoin and Zcash. Bullish sentiment is fueled by discussions around institutional adoption, ETF possibilities, and the anticipation of a potential 'alt season'. Traders are actively monitoring price movements, speculating on upcoming resistance breaks and potential for substantial upward momentum.

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Fresenius Medical Care AG - ADR

Fresenius Medical Care AG & Co. KGAA

Fresenius Medical Care ($FMS) is trending amid discussions surrounding potential catalysts and growth opportunities, particularly related to adoption of DefenCath and CMS policy changes. The community is focused on the potential for increased revenue from infection prevention strategies and the impact of government regulations on the dialysis sector. Discussions also mention possible strategic moves and partnerships, including potential relationships with companies like CorMedix ($CRMD).

Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.

Evaxion A/S - ADR

Evaxion Biotech

EVAX is trending due to positive data for its AI-designed personalized cancer vaccine and a new CEO appointment expected to catalyze partnerships. The community speculates on potential deals before year-end, citing a consistent pattern observed in small-cap biotechs. Discussions also highlight the company's extended cash runway and expanding R&D pipeline.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the crypto market experiences volatility, sparking debates about its correlation with Bitcoin and potential decoupling. Community members are discussing upcoming ISO 20022 compliance and speculating on the impact of potential XRP ETFs. Sentiment is mixed, with some investors expressing long-term confidence while others are concerned about short-term price action and overall market conditions.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending due to ongoing discussions about its financial performance and future prospects, especially surrounding the impact of TDAPA (Transitional Drug Add-on Payment Adjustment) on DefenCath sales. The community is focused on the company's growth rates, institutional ownership, and potential catalysts such as real-world evidence data and expansion into new markets, alongside external factors, including CMS (Centers for Medicare & Medicaid Services) decisions.

Teucrium Trading, LLC - Teucrium Corn Fund

CORN is trending due to options activity and actionable trade alerts, with community members weighing in on potential profit margins. Some traders are discussing strategies involving puts and calls, particularly on down market days, as a hedge. Broader discussion includes grain reports and analysis of market factors influencing corn prices.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eagle Health Investments LP Invests $11.20 Million in BridgeBio Pharma, Inc. $BBIO

Eagle Health Investments LP acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the second quarter, according to its most recent filing with the Securities...

Ensign Peak Advisors Inc Sells 534,060 Shares of BridgeBio Pharma, Inc. $BBIO

Ensign Peak Advisors Inc lowered its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 28.9% in the second quarter, according to its most recent 13F filing with the Securities...

BridgeBio Pharma (NASDAQ:BBIO) Director Sells $666,500.00 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Randal Scott sold 10,000 shares of BridgeBio Pharma stock in a transaction dated Monday, November 17th. The stock was sold at an...

Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) Director Sells 40,599 Shares of Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Andrew Lo sold 40,599 shares of the company's stock in a transaction dated Monday, November 17th. The shares were sold at an average...

BridgeBio Pharma (NASDAQ:BBIO) Director Sells $3,612,950.00 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Andrew Lo sold 55,000 shares of BridgeBio Pharma stock in a transaction dated Tuesday, November 18th. The shares were sold at an...

BridgeBio Pharma, Inc. $BBIO Shares Sold by KBC Group NV

KBC Group NV lowered its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 98.0% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned...

Savant Capital LLC Acquires Shares of 5,051 BridgeBio Pharma, Inc. $BBIO

Savant Capital LLC bought a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and...

Envestnet Asset Management Inc. Boosts Position in BridgeBio Pharma, Inc. $BBIO

Envestnet Asset Management Inc. grew its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 204.1% in the 2nd quarter, according to the company in its most recent disclosure...

BridgeBio Pharma (NASDAQ:BBIO) CFO Sells $1,125,433.64 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CFO Thomas Trimarchi sold 16,934 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of...

BridgeBio Pharma (NASDAQ:BBIO) CFO Thomas Trimarchi Sells 16,934 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CFO Thomas Trimarchi sold 16,934 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average...

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BBIO
BridgeBio Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BBIO News

BBIOBridgeBio Pharma Inc